OS Therapies & EVERSANA Partner to Commercialize OST-HER2 in the US for Pediatric Osteosarcoma

Shots:OS Therapies joined hands with EVERSANA to commercialize OST-HER2 in the US for the treatment of pediatric lung metastatic osteosarcomaThis partnership leverages EVERSANA’s integrated commercialization platform, including market access, medical affairs, field deployment, patient services, and stakeholder engagement enabling OS Therapies to bring OST-HER2 to market rapidly and cost-effectivelyOS Therapies recently secured…

ByPrince GiriJune 11, 2025

SPOTLIGHT

Reuters Pharma 2025: Pre-Conference Talks Featuring Mike Ryan

Mike Ryan Executive Vice President at Eversana shares a glimpse of his upcoming panel discussion at the Reuters Pharma 2025 event on “28 countries for 2 years: Explore and evaluate the trade-offs in European launch sequencing”Mike elaborates on Eversana’s comprehensive offerings that help biopharmaceutical companies tap into the complex European market. He highlights the…

ByHimanshu SehgalApril 8, 2025

OS Therapies & EVERSANA Partner to Commercialize OST-HER2 in the US for Pediatric Osteosarcoma

Reuters Pharma 2025: Pre-Conference Talks Featuring Mike Ryan

Contact US

OUR INFORMATION

FOLLOW US